Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide
Background: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE). Asymmetric dimethylarginine (ADMA) has been associated with cardiovascular events in SLE patients and is a strong predictor of the progression of chronic kidney disease. However, whether...
Main Authors: | Li Zhang, Kaichong Zhang, Wei Dong, Ruizhao Li, Renwei Huang, Hong Zhang, Wanxin Shi, Shuangxin Liu, Zhuo Li, Yuanhan Chen, Zhiming Ye, Xinling Liang, Xueqing Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-07-01
|
Series: | Kidney Diseases |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/509767 |
Similar Items
-
TO COMPARE THE EFFICACY OF MYCOPHENOLATEMOFETYL WITH CYCLOPHOSPHAMIDE IN THE MANAGEMENT OF LUPUS NEPHRITIS
by: Dilshad Muhammad, et al.
Published: (2014-12-01) -
Asymmetric Dimethylarginine: Clinical Applications in Pediatric Medicine
by: You-Lin Tain, et al.
Published: (2011-02-01) -
Mycophenolate versus cyclophosphamide for lupus nephritis
by: M Sahay, et al.
Published: (2018-01-01) -
Symmetrical (SDMA) and asymmetrical dimethylarginine (ADMA) in sepsis: high plasma levels as combined risk markers for sepsis survival
by: Martin Sebastian Winkler, et al.
Published: (2018-09-01) -
Association of dimethylarginines and mediators of inflammation after acute ischemic stroke
by: Chen Shufen, et al.
Published: (2012-11-01)